Abbott Northwestern Hospital is a 686-staffed bed teaching and specialty hospital based in Minneapolis, Minnesota. It is a part of the Allina Health network of hospitals and clinics.
RESEARCH QUESTION:What are Black women's experiences when seeking reproductive health care in Iowa? DESIGN:Narrative-style qualitative research. METHODS:Adult Black women in Iowa were recruited for phone interviews. Data was analysed using within and across case methodology. RESULTS:Clinical experiences included suboptimal healthcare, a lack of information, and being treated differently because they were Black. Consequences included not returning to the provider, mistrust of providers and health systems, but also greater self-advocacy. CONCLUSION:The findings from this study are illustrative of the realities that Black women in Iowa faced when seeking reproductive healthcare. IMPLICATIONS FOR THE HEALTH PROFESSIONALS AND PATIENT CARE:Women in this study voiced a need for health professionals to actively listen to people under their care, demonstrate genuine human concern, and adopt person-centred and shared decision-making models for care delivery. Recommended system changes include a need to further diversify the workforce, improve training for the care of persons of colour, and develop better clinical tools that consider different skin and body types. PATIENT AND PUBLIC INVOLVEMENT:Members of the public were involved in the study design and interpretation of findings. Their contributions included providing feedback on research proposal drafts and attending research team meetings to ensure that the research itself did not contribute to racism. Community members with the shared identity of research participants also provided an interpretive lens for the data, crucial for the understanding of white research team members who have not experienced racism.
RATIONALE:Delirium among hospitalized patients is a common but largely preventable condition resulting in poor outcomes and increased healthcare costs. Research suggests that addressing the nursing knowledge gap regarding delirium and implementing prevention tactics can help prevent delirium from developing. AIM OF INITIATIVE:This evidence-based practice project aimed to reduce the incidence of delirium through early identification of delirium development and implementation of tailored nursing interventions. IMPLEMENTATION PROCEDURE:A pre-survey was distributed to assess the nursing staff's knowledge, attitudes, and behaviors regarding delirium. Education was developed based on survey results and tailored to address knowledge gaps and barriers to implementing existing delirium prevention tactics. The education was delivered in various formats and focused on delirium risk factors and the early implementation of evidence-based delirium prevention strategies. The education reinforced the clinical nurses' process of ordering and implementing a delirium prevention bundle and sleep promotion orders while also integrating new knowledge on risk factors and hallmarks of delirium. OUTCOMES:Clinical nurses' knowledge, attitudes, and self-reported behaviors showed improvement in the post-implementation survey. Delirium rates were reduced by 11.8%. After delirium developed, the patients' length of stay was reduced by 0.75 days. IMPLICATIONS FOR PRACTICE:Proactive, preventative measures can improve clinical outcomes and trajectories related to delirium. Therefore, continuing nursing education on delirium prevention strategies can improve patients' health outcomes in the acute care setting.
AIMS:The Evoque™ transcatheter tricuspid valve replacement (TTVR) system demonstrated superiority over optimal medical treatment (OMT) in the TRISCEND II trial. We aimed to evaluate the cost-effectiveness of TTVR in patients with severe Tricuspid Regurgitation (TR) from the French healthcare perspective. METHODS AND RESULTS:A state-transition Markov model was developed to assess the cost-effectiveness of Evoque™ TTVR versus OMT alone over a lifetime horizon. The modeled cohort reflected the TRISCEND II population. Health states were defined by TR severity (none/trace, mild, moderate, severe) and death. Transition probabilities, adverse events, and hospitalisation rates were informed by TRISCEND II. Long-term survival outcomes were extrapolated by TR severity using published data. Utilities were estimated from NYHA class distribution. Costs and health outcomes were discounted at 2.5% annually.Evoque™ was associated with an incremental 1.76 life-years gained (LYG) and 1.63 quality-adjusted LYG (QALY). Incremental costs were €39,382 driven by device acquisition and procedure costs, resulting in an incremental cost-effectiveness ratio (ICERs) of €22,327/LYG and €24,109/QALY gained. Assuming no mortality difference in extrapolations, the ICER would increase to €86,428/QALY (+258%). The model was highly sensitive to assumptions on time horizon, utility, discount rate and post-trial mortality extrapolation, leading to major uncertainty. CONCLUSION:Evoque™ may represent a cost-effective strategy in severe TR patients, however this should be interpreted with caution, as results rely heavily on extrapolated data and are subject to high structural and parameter uncertainty. The projected long-term benefits are largely model driven rather than empirically demonstrated, emphasising the need for extended follow-up data.
BACKGROUND:Transcatheter mitral valve replacement (TMVR) offers a potential treatment option for select patients with mitral regurgitation (MR) deemed unsuitable for surgery or transcatheter repair, but data are limited on its long-term durability and performance. AIMS:We evaluated 5-year outcomes from the global Pilot Study with the Intrepid transapical (TA) TMVR system. METHODS:This multicentre, single-arm study evaluated the early-generation Intrepid TA system in patients with symptomatic ≥moderate-severe MR at high risk for mitral valve (MV) surgery. Echocardiograms and clinical events were independently adjudicated, and patients were followed for up to 5 years. RESULTS:Ninety-five patients were enrolled at 21 sites between 2015 and 2019. The mean age was 74.0±9.2 years, 43.2% of patients were female, the mean Society of Thoracic Surgeons Predicted Risk of Mortality score was 6.5±4.8%, 57.9% had prior heart failure hospitalisation (HFH), and 88.4% were in New York Heart Association (NYHA) Functional Class III/IV. Secondary MR was present in 78.7%, and 76.6% had a left ventricular ejection fraction ≤50%. Up to 5 years, all-cause mortality was 66.7% and HFH was 55.4%, with one 30-day MV reintervention (1.1%). Haemodynamic valve deterioration occurred in 1.4%, the median MV mean gradient remained stable at 3.6 mmHg (first and third quartiles: 3.0, 4.8 mmHg), ≤mild MR was present in 100% of patients, and no patient experienced paravalvular leak. NYHA Functional Class I/II was maintained in 84.6%. CONCLUSIONS:In this 5-year follow-up of the early-generation Intrepid TA TMVR system, we observed sustained MR reduction, durable haemodynamic valve performance, and improved functional status among survivors. The APOLLO (ClinicalTrials.gov: NCT03242642) and APOLLO-EU (NCT05496998) trials using the transfemoral Intrepid system will further determine the role of TMVR in managing this high-risk patient population. CLINICALTRIALS:gov: NCT02322840.